Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 672 participants.
Also called NCT05102149
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 672 participants
- Sponsor
- Registry
-
NCT05102149
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China, Hong Kong SAR China, Taiwan
- Registry status
- Unknown status
Technical summary
Registry record NCT05102149. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-30 (actual); primary completion 2023-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- PB-201
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- PB-201 matched placebo
- Intervention (Drug)
- Vildagliptin matched placebo
- Lead sponsor
- PegBio Co., Ltd.
Record details
- Record id
cardio:ct-nct05102149- Content hash
343aa89ab8dad17e4d5c2241bddda7e82f9fa47515255cb3426fecad81862415